LEGEND-2 Updated Analysis: Phase I Study of LCAR-B38M CAR T-Cell Therapy in Patients With R/R Multiple Myeloma

December 1-4, 2018; San Diego, California
Investigational BCMA-targeted CAR T-cell therapy provides tolerable safety profile and high ORR in this early-phase study
Format: Microsoft PowerPoint (.ppt)
File Size: 216 KB
Released: December 11, 2018

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Incyte
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Seagen
Takeda Oncology

Related Content

Downloadable slideset from S. Vincent Rajkumar, MD and Thomas G. Martin, MD, on considerations for treatment of multiple myeloma at first relapse, provided by Clinical Care Options (CCO)

Thomas G. Martin, MD S. Vincent Rajkumar, MD Released: December 29, 2022

Webcast from a live meeting series presented by Dr Sarah Holstein on advancements in first-line care for newly diagnosed multiple myeloma, from Clinical Care Options (CCO)

Sarah A. Holstein, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Phase I/II trial of mezigdomide + dexamethasone in relapsed/refractory multiple myeloma, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 19, 2022

Long-term PFS data exploring duration of lenalidomide maintenance therapy in patients with multiple myeloma after ASCT, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings